Survival by treatment and by prognostic risk score
| Risk groups . | 5-year survival, % (95% CI) . | ||
|---|---|---|---|
| IFN-α + LDAC . | IFN-α . | P . | |
| Sokal RR | |||
| Low | 79 (70-88) | 72 (61-83) | .35 |
| Intermediate | 62 (48-76) | 64 (49-79) | .56 |
| High | 55 (40-70) | 51 (33-69) | .83 |
| P, trend | .0004 | .0134 | |
| Euro RR | |||
| Low | 82 (75-90) | 75 (66-84) | .30 |
| Intermediate | 63 (51-75) | 67 (55-79) | .18 |
| High | 51 (29-72) | 57 (36-78) | .69 |
| P, trend | .0144 | .0412 | |
| Risk groups . | 5-year survival, % (95% CI) . | ||
|---|---|---|---|
| IFN-α + LDAC . | IFN-α . | P . | |
| Sokal RR | |||
| Low | 79 (70-88) | 72 (61-83) | .35 |
| Intermediate | 62 (48-76) | 64 (49-79) | .56 |
| High | 55 (40-70) | 51 (33-69) | .83 |
| P, trend | .0004 | .0134 | |
| Euro RR | |||
| Low | 82 (75-90) | 75 (66-84) | .30 |
| Intermediate | 63 (51-75) | 67 (55-79) | .18 |
| High | 51 (29-72) | 57 (36-78) | .69 |
| P, trend | .0144 | .0412 | |
The risk was calculated according both available formulations: the old Sokal30 formulation, derived from conventionally treated cases, and the new Euro31 formulation, derived from IFN-α-treated cases. A significant risk stratification was achieved with either risk system, but within each risk group there was no difference between IFN-α plus LDAC and IFN-α alone.
CI indicates confidence interval. Other abbreviations are explained in Table 1.